Pomalidomide-C4-NH2
[CAS# 1957236-34-8]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrimidine compound >> Amine
• Name: Pomalidomide-C4-NH2
• Synonyms: 4-(4-aminobutylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
• Molecular Formula: C₁₇H₂₀N₄O₄
• Molecular Weight: 344.37
• CAS Registry Number: 1957236-34-8
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCN

Properties

• Density: 1.4±0.1 g/cm³, Calc.^*
• Index of Refraction: 1.652, Calc.^*
• Boiling Point: 641.4±55.0 ºC (760 mmHg), Calc.^*
• Flash Point: 341.7±31.5 ºC, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Discovory and Applicatios

Pomalidomide-C4-NH2 is a derivative of pomalidomide, a well-known immunomodulatory drug that has been widely studied for its therapeutic potential in various diseases, particularly cancer and autoimmune disorders. This compound is characterized by an amine group (-NH2) attached to the C4 position of the pomalidomide molecule, which may alter its pharmacological properties and biological activity.

Pomalidomide itself was discovered as part of ongoing research into thalidomide derivatives, a class of compounds with notable anti-inflammatory, anti-angiogenic, and anti-tumor properties. Thalidomide was originally developed as a sedative, but its teratogenic effects led to its withdrawal from the market. However, further studies revealed its potential in treating conditions like multiple myeloma and leprosy, which led to the development of its derivatives, including pomalidomide.

Pomalidomide-C4-NH2, as a modified form of pomalidomide, likely underwent structural optimization to enhance certain aspects of its activity or reduce undesirable side effects. The introduction of the amine group at the C4 position might impact the compound's interaction with cellular targets, including immune system cells such as T-cells and natural killer cells, which are known to be influenced by pomalidomide and its derivatives. This modification could potentially lead to improved efficacy in promoting immune cell activation or suppression of tumor growth in conditions like multiple myeloma.

In terms of applications, pomalidomide-C4-NH2 is expected to be of interest in both therapeutic and research contexts. In therapy, similar to other pomalidomide derivatives, it may be explored as an agent for treating hematological cancers, including multiple myeloma and myelodysplastic syndromes, where its immunomodulatory effects could boost anti-tumor immune responses. Additionally, the presence of the amine group could enhance its solubility, stability, or ability to cross cell membranes, making it an attractive candidate for further drug development.

From a research perspective, pomalidomide-C4-NH2 may also serve as a valuable tool for studying the molecular mechanisms underlying the activity of immunomodulatory drugs. By comparing its effects to those of other derivatives or parent compounds, researchers can gain insights into the relationship between chemical structure and therapeutic activity, which is crucial for designing the next generation of drugs with more targeted actions and fewer side effects.

In conclusion, pomalidomide-C4-NH2 is an important derivative of pomalidomide with potential applications in cancer therapy and immunomodulation. Its modification at the C4 position with an amine group may enhance its biological activity, making it a valuable compound for drug development and research into immune system-based treatments for cancer and autoimmune diseases.